You can buy or sell VIVUS and other stocks, options, ETFs, and crypto commission-free!
VIVUS, Inc. engages in the development and commercialization of novel therapeutic products. The firm's products are indicated for the treatment of obese and overweight patients, exocrine pancreatic insufficiency, and erectile dysfunction. Read More Its products include PANCREAZE, Qsymia, and STENDRA/SPEDRA. The company was founded by Virgil A. Place in April 16, 1991 and is headquartered in Campbell, CA.
52 Week High
52 Week Low
Yahoo FinanceMay 6
VVUS: New Ideas for Established Portfolio
By John Vandermosten, CFA NASDAQ:VVUS READ THE FULL VVUS RESEARCH REPORT We are initiating coverage of VIVUS, Inc. (VVUS) with a $10.00 price target based on our revenue forecasts for approved products. In addition to a portfolio of weight loss, exocrine pancreatic insufficiency (EPI) and erectile dysfunction (ED) solutions, Vivus maintains a development program for pulmonary arterial hypertension (PAH). Existing product Qsymia and recently acquired product Pancreaze are expected to be the main rev...
Seeking AlphaApr 30
VIVUS, Inc. (VVUS) CEO John Amos on Q1 2019 Results - Earnings Call Transcript
VIVUS, Inc. (NASDAQ:VVUS) Q1 2019 Earnings Conference Call April 30, 2019 4:30 PM ET Company Participants David Carey - Managing Director, Investor Relations, Lazar Partners John Amos - Chief Executive Officer Mark Oki - Chief Financial Officer Santosh Varghese - Chief Medical Officer Conference Call Participants John Vandermosten - Zacks Small Capital Research Operator Good afternoon, and welcome to the VIVUS First Quarter 2019 Financial Results Conference Call. Today's call is being recorded. Fo...
Expected Aug 6, After Hours